Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 484

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 19
Chunk 484
---
 (4)                                 ​   ​    —         ​    ​    3,643     ​    ​    (2,374)
Costs (-)/deduction of costs relating to our 50/50 profit/(cost) share mechanism (5)        ​   ​    ​         ​    ​    ​         ​    ​    ​      
included in sales and marketing expenses                                                    ​   ​    —         ​    ​    —         ​    ​    31     
included in research and development expenditure                                            ​   ​    —         ​    ​    —         ​    ​    (31)   
Purchase of raw materials, semi-finished products and finished products of Jyseleca         ​   €    —         ​    €    —         ​    €    13,539 
​
(1) Consisting on December 31, 2024 mainly of a royalties receivable of €2.2 million, consisting on December 31, 2023 of filgotinib development cost sharing receivables of €2.5 million and royalties receivables of €2.4 million, consisting on December 31, 2022 of €5.1 million of filgotinib development cost sharing receivables and €2.6 million royalties receivables.(2) Upfront and milestone payments recognized in accordance with the percentage of completion of the underlying obligation.(3) Shown as decrease of research and development expenditure.(4) Net amount shown as an (increase)/decrease of research and development expenditure
.(5) Profit/cost share mechanism came to an end beginning of 2022.As at December 31, 2023 we had two outstanding performance obligations under IFRS 15 towards Gilead, being the performance obligation related to our drug discovery platform and the performance obligation relating to filgotinib before its transfer to Alfasigma on January 31, 2024, following the closing of the transaction for the transfer of the Jyseleca® business. The remaining deferred income for the performance obligation relating to filgotinib, amounting to €26.3 million at December 31, 2023, was recognized in revenue in 2024. The outstanding deferred income balance at December 31, 2024 for the drug discovery platform amounted to €1.1 billion.A detailed explanation of our transactions with Gilead in 2022, 2023 and 2024 can be found in the section of this annual